cc
 
bar

program

  test
bar
 
 

Alzheimer's Disease—Evaluation
and Management

Practical Approaches and Considerations for Optimizing Care in the Assisted Living Environment

Analysis and Guidance from the Alzheimer’s Disease, Assisted Living (AD-AL)
Expert Consensus Panel—The PROCLAIM Approach to Optimizing
Assessment and Intervention in Individuals with Dementia

Program CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This program is intended for neurologists, geriatricians,
and primary care physicians, as well as program directors, licensed practical
nurses, nurse practitioners, physician assistants and pharmacists in the
assisted living environment.

Educational Objectives:

  • Physicians will learn how to apply new evidence and the results of clinical
    trials to manage patients with Alzheimer’s Disease
  • Physicians will learn to risk stratify patients with Alzheimer’s Disease and
    Identify optimal therapy
  • Physicians will learn the clinical implications of Alzheimer’s Disease in the
    assisted living environment
  • Physicians will learn to apply treatment triggers and national guidelines to
    effectively manage patients with Alzheimer’s Disease

Needs Assessment:

The rationale for producing this CME-certified clinical monograph focusing
on Alzheimer’s Disease management is based on the results of a needs
assessment survey conducted in 2006. Results of this clinical needs assessment
survey indicated an interest on the part of specialists in topics related
to detection, screening, risk stratification, patient selection, monitoring, and
management of patients with Alzheimer’s Disease in the Assisted Living
environment.

Credit Designation Statement:

This activity has been planned and implemented in accordance with the
Essentials and Standards of the Accreditation Council for Continuing Medical
Education (ACCME) through the joint sponsorship of the University of
Massachusetts Medical School (UMMS). The UMMS is accredited by ACCME
to provide continuing medical education for physicians.
The UMMS designates this continuing medical education activity for up to 6
credit hours in Category 1 toward the Physicians Recognition Award of the
American Medical Association. Each physician should claim only those hours
of credit that he/she actually spent in the educational activity.
Effective Dates: This material is authorized for CME credits beginning
December 1, 2007, and expiring December 1, 2008.

Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education.
Provided by an Independent Educational Grant from Brookdale Senior Living.

In accordance with the Standards of the Accreditation Council for Continuing
Medical Education (ACCME) and the guidelines of the Association of
American Medical Colleges (AAMC), it is the policy of the University of
Massachusetts Medical School to disclose whatever interest or affiliation a
speaker might have with any commercial organization whose products or
services are related to the subject matter being presented.

Conflict of Interest Disclosures:

Lori Daiello reports she is on the Speaker’s Bureau of Abbott Labs, Forest Labs, Pfizer, and Eli Lilly; and a consultant for Abbott Labs, Forest Labs, and Eli Lilly. No others to disclose.

AD-AL Panel Chairperson:
Sharon Roth Maguire MS, APRN-BC, GNP,
Senior Director Healthcare and Resident Services, Brookdale Senior Living/Milwaukee Operating Group, Assisted Living & Memory Care, Milwaukee, WI

Distinguished AD-AL Panel Members:
Anna Treinkman MSN, RN, APN,
Nurse Practitioner, Rush Alzheimer’s Disease Center, Immediate Past President, NCGNP, Chicago, IL;
Lori A. Daiello Pharm.D, BCPP, Geriatric Psychopharmacology Specialist, Pharmacotherapy Solutions, Providence, RI
Bernie Cavis, B.S., Dementia Product Line Director, Brookdale Senior Living, Bradenton, FL;
Joni Lee, Division Director of Health Services & Quality, Brookdale Senior Living, Redmond WA
Donna J. Rose, Assisted Living/Memory Care, Western Division Memory Care Specialist, Brookdale Senior Living
Rita Carter, Division Director Healthcare Service and Quality, Brookdale Senior Living, Inc., Kokomo, IN
Juliet Holt, MA Director of Dementia Care and Programs, Brookdale Senior Living, Chicago, IL
Paul Stander, MD FACP, Chief Medical Officer, Banner Health Systems, Phoenix, AZ
Stephen L. Axelrod MD, V.P. Strategy and Business Development, SeniorMed, Aurora, CO.
Jane G. Kirby B.A., Divisional Memory Care Specialist, Brookdale Senior Living, Williamsville, New York

Legal Disclaimer and Pracitce Application Caution:

Clinical Consensus Update is publication intended for educational value only,. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This publication is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This publication is not intended for use by the layman. Opinions expressed herein are not necessarily those of this publication, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

  test
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
Abilify
activities of daily living
AD
dementia
AD-AL Consensus Panel Patients Suspected of Alzheimer’s Dementia
ADLs
Alcoholism
Alprazolam
Alzheimer’s
Alzheimer’s Disease
Ambien
Amitriptyline
Anafranil
Anemia
Antidepressants
antipsychotic
Antipsychotics
Aphasia
Aricept
Aripiprazole
Assisted Living
Ativan
beta-amyloid
brain
Buproprion
Celexa
Chlorpromazine
cholinesterase
Citalopram
Clomipramine
Clonazepam



















Cymbalta
Dalmane
Delirium
Depression
Desipramine
Desyrel
Diagnostic and Statistical Manual
Diastat
Diazepam
donepezil
Donepezil
Doral
Doxepin
Drug-induced delirium
DSM-IV
Duloxetine
Effexor
Effexor XR
Escitalopram
Estazolam
Eszopiclone
Exelon
Fluoxetine
Flurazepam
Fluvoxamine
galantamine
Galantamine
Geodon
Halcion
Haldol
Haloperidol
head trauma
Imipramine

Infection
Invega
Klonopin
Lexapro
Lorazepam
Lunesta
Medication-related
Mellaril
Memantine
Mental retardation
Metabolic organic failure (liver or kidney disease)
Namenda
Nefazodone
Neuroleptics
NMDA
N-methyl-D-aspartate
Norpramin
Nortriptyline
Nutritional deficiencies
Olanzapine
Oxazepam
Paliperidone
Pamelor
Parkinsonian
Paroxetine
Paxil
Paxil CR
PROCLAIM
ProSom
Prozac
Prozac Weekly
Psychosis
Quazepam
Ramelteon

Razadyne ER
Remeron
Remeron SolTab,
Restoril
Rivastigmine
Rozerem
sedative hypnotics.
Sensory impairments
Serax
Sertraline
Sinequan
Sonata
Stroke
Structural CNS conditions
Substance abuse
Temazepam
Thioridazine
Thorazine
Thyroid disorders
Tofranil
Trazodone
Triazolam
Valium
Vanatrip
Venlafaxine
Wellbutrin
Wellbutrin SR
Xanax
Xerostomia
Zaleplon
Ziprasidone
Zoloft
Zolpidem
Zyprexa
Zyprexa IntraMuscular
Zyprexa Zydis